Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma

NCT ID: NCT06623474

Last Updated: 2024-10-09

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 900 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-07-01
• Study Completion Date: 2032-07-01

Brief Summary

As one of the common malignant tumors in China, primary liver cancer, whose incidence rate and mortality rate are always in the top five, is seriously threatening the health of people. Therefore, early diagnosis and treatment of primary liver cancer are of great significance. In recent years, the incidence of primary liver cancer, which is caused by hepatic steatosis or metabolic dysfunction-related liver disease, is increasing year by year, and it has become one of the fastest rising causes in some developed countries. More and more studies have also confirmed that the levels of different kinds of lipids and their metabolites are correlated with the development of hepatocellular carcinoma. In this study, the researchers performed qualitative and quantitative analyses of various common lipid metabolites in plasma and liver cancer tissues of hepatic resection patients with hepatocellular carcinoma, collected tumor-related pathological data from the patients, and investigated the correlation between the lipid metabolites and the development of hepatocellular carcinoma, in order to provide a new idea for the early diagnosis and treatment of primary hepatocellular carcinoma, as well as for screening of hepatocellular carcinoma markers.

Conditions

Hepatocellular Carcinoma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Patients diagnosed with hepatocellular carcinoma

Patients diagnosed with hepatocellular carcinoma according to the guidelines for the diagnosis of primary liver cancer

diagnosed by traditional diagnostic markers（such as AFP or CT etc.）

Intervention Type: DIAGNOSTIC_TEST

A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).

Patients diagnosed with non-hepatocellular carcinoma otherwise requiring hepatic resection

Patients who can be excluded from the diagnosis of hepatocellular carcinoma according to the guidelines for the diagnosis of primary liver cancer but required hepatic resection for other liver diseases

diagnosed by traditional diagnostic markers（such as AFP or CT etc.）

Intervention Type: DIAGNOSTIC_TEST

A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).

Interventions

diagnosed by traditional diagnostic markers（such as AFP or CT etc.）

A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).

Intervention Type: DIAGNOSTIC_TEST

Other Intervention Names

diagnosed by lipid metabolites

Eligibility Criteria

Inclusion Criteria

• Patients aged 18-80 years old undergoing hepatic resection for hepatocellular carcinoma (diagnostic criteria for hepatocellular carcinoma refer to the guidelines for the diagnosis and treatment of primary hepatocellular carcinoma).
• Voluntary signing of informed consent

Exclusion Criteria

• In the judgment of the investigator, they are not suitable to participate in this study.
• Patients with hepatic malignant tumors with invasion of the main portal vein and its first-order branches, the common hepatic duct and its first-order branches, the main hepatic vein and the inferior vena cava, or extrahepatic metastases.
• Surgery with biliary tract exploration or reconstruction in the presence of biliary obstruction.
• Surgery combined with splenectomy or splenic artery ligation
• Preoperative combination of cardiac, pulmonary, renal and other organs with major underlying diseases.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nanfang Hospital, Southern Medical University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Nanfang Hospital

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Kai Wang, Doctor

Role: CONTACT

kaiwang@smu.edu.cn

13710574386

Facility Contacts

Kai Wang, Doctor

Role: primary

kaiwang@smu.edu.cn

13710574386

Other Identifiers

NFEC-2024-361

Identifier Type: -

Identifier Source: org_study_id